gip/glp-1 Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1 Science Behind GLP 1 GIP
Description
As part of its investor day on Thursday, Cigna's Evernorth arm announced an expansion to its GLP-1 management solution as well as the launch of a new behavioral-health-focused medical group
Oral semaglutide showed cardiovascular safety profile, with significant reduced risk of death from cardiovascular events
Apitegromab (SRK-015), an investigational new drug developed by Scholar Rock, is a fully human IgG4 monoclonal antibody that specifically binds to human Pro-GDF8 or latent GDF8 without binding to mature GDF8 or other closely related growth factors
Based on: Lebrun LJ, Lenaerts K, Kiers D, Pais de Barros JP, Le Guern N, Plesnik J, et al
